Results 21 to 30 of about 157,671 (305)

Guillain-Barre Syndrome and COVID-19 Vaccine: A Report of Nine Patients

open access: yesBasic and Clinical Neuroscience, 2021
Introduction: Guillain-Barre Syndrome (GBS) is an autoimmune acute inflammatory demyelinating polyneuropathy usually elicited by an upper respiratory tract infection.
Narges Karimi   +12 more
doaj  

Equity research: AstraZeneca PLC [PDF]

open access: yes, 2023
Projeto de mestrado em FinançasO objetivo deste relatório é avaliar a AstraZeneca PLC e a sua estrutura seguirá os padrões do Instituto CFA. Esta empresa foi selecionada principalmente por dois motivos: primeiro, a indústria farmacêutica está em ...
Campião, Ana Carolina Silva
core  

Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database

open access: yesVaccines, 2021
Vaccination against COVID-19 is the cornerstone of controlling and mitigating the ongoing pandemic. Thrombotic adverse events linked to Moderna, Pfizer and the Oxford-AstraZeneca vaccine have been documented and described as extremely rare.
Mansour Tobaiqy   +3 more
doaj   +1 more source

Kvaliteten til AstraZeneca-vaksinen - flere spørsmål enn svar [PDF]

open access: yes, 2021
Formålet med studien har vært å vurdere kvaliteten til AstraZeneca-vaksinen ut ifra resultatene og bivirkningene som ble rapportert under de kliniske studiene og bivirkningene som ble rapportert etter at vaksinen har blitt godkjent for administrering ...
Czech, Ilona
core   +1 more source

Acquired Thrombotic Thrombocytopenic Purpura after AstraZeneca Vaccine: a Case Report

open access: yesCaspian Journal of Internal Medicine, 2022
Background: Rare cases of acquired thrombotic thrombocytopenic purpura (aTTP) have been reported since the administration of the COVID-19 vaccination. Based on our information, the present study provides the first case report of aTTP developed after the ...
Fatemeh Yaghoobi, Davood Dalil
doaj  

Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma

open access: yesOncoImmunology, 2021
The potential for durvalumab, a programmed cell death ligand-1 (PD-L1)-blocking monoclonal antibody, to treat head and neck squamous cell carcinoma (HNSCC) is being evaluated in multiple clinical trials.
Rosalinda Arends   +7 more
doaj   +1 more source

Meta-Analysis Design and Results in Real Life: Problem Solvers or Detour to Maze. A Critical Review of Meta-Analysis of DAPT Randomized Controlled Trials. [PDF]

open access: yes, 2019
Therapeutic strategies - such as duration of dual antiplatelet therapy after coronary artery stenting - usually generate a large quantity of meta-analyses. The meta-analyses that include the same randomized clinical trials should produce similar results.
Ramakrishna, Harish   +9 more
core   +1 more source

PATRÓN DE PRESCRIPCIÓN DE AGONISTAS BETA-2 DE ACCIÓN CORTA Y POTENCIALES EFECTOS SOBRE EL CONTROL DEL ASMA: COHORTE ARGENTINA DEL ESTUDIO SABINA III

open access: yesRevistas Argentina de Medicina, 2022
Conflictos de intereses El doctor Mattarucco es orador de AstraZeneca y ha realizado o realiza investigación clínica para AstraZeneca, GSK y Novartis. El doctor Goffredo ha recibido honorarios por charlas de AstraZeneca y GSK. El doctor Zunino es orador
Walter Mattarucco
doaj   +2 more sources

AstraZeneca/skywalkR-graph-features: v1.0.0

open access: yes, 2022
Example notebooks that illustrate how to generate knowledge-based features.
Michaël Ughetto, Anna Gogleva
core   +1 more source

External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry [PDF]

open access: yes, 2023
AIMS: THEMIS is a double-blind, randomized trial of 19,220 patients with diabetes mellitus and stable coronary artery disease (CAD) comparing ticagrelor to placebo, in addition to aspirin.
Simon, Tabassome   +27 more
core   +1 more source

Home - About - Disclaimer - Privacy